정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 562 | Completed | Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19) | Covid19 | Drug: anti-SARS-CoV-2 IgY Drug: Placebo |
Phase 1 | Stanford University | OTHER | 48 | All | 18 Years ~ 45 Years | Linear Clinical Research - Harry Perkins Research Institute, Nedlands, Western Australia, Australia |
| 561 | Active, not recruiting | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19 | SARS-CoV2 | Biological: SAB-185 Other: Normal Saline |
Phase 1 | SAb Biotherapeutics, Inc., Biomedical Advanced Research and Development Authority, Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) | INDUSTRY | 21 | All | 18 Years ~ 60 Years | Quantum Clinical Trials, Miami Beach, Florida, United States University of Nebraska Medical Center, Omaha, Nebraska, United States Sanford Health, Sioux Falls, South Dakota, United States |
| 560 | Active, not recruiting | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants | SARS-CoV2 | Biological: SAB-185 Other: Normal saline |
Phase 1 | SAb Biotherapeutics, Inc., Department of Health and Human Services, Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) | INDUSTRY | 28 | All | 18 Years ~ 60 Years | Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States SUNY Upstate Medical University, Syracuse, New York, United States ICON Early Phase Services, San Antonio, Texas, United States |
| 559 | Completed | Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 | COVID-19 | Drug: BRII-196 Drug: Placebo |
Phase 1 | Brii Biosciences Limited, TSB Therapeutics (Beijing) CO.LTD | INDUSTRY | 16 | All | 18 Years ~ 49 Years | Investigative Site, Beijing, Beijing, China |
| 558 | Completed | Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198 | COVID-19 | Drug: BRII-198 Drug: Placebo |
Phase 1 | Brii Biosciences Limited, TSB Therapeutics (Beijing) CO.LTD | INDUSTRY | 17 | All | 18 Years ~ 49 Years | Investigative Site, Beijing, Beijing, China |
| 557 | Completed | Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants | Covid19 | Drug: BGB DXP593 Drug: Placebo |
Phase 1 | BeiGene | INDUSTRY | 18 | All | 18 Years ~ 60 Years | Q Pharm Pty Limited, Herston, Queensland, Australia |
| 556 | Recruiting | Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults | Covid19 | Biological: EuCorVac-19 Other: Normal Saline |
Phase 2 | EuBiologics Co.,Ltd | INDUSTRY | 280 | All | 19 Years ~ 75 Years | The Catholic University of Eunpyeong St.Mary's Hospital, Seoul, Korea, Republic of |